This study investigates neoadjuvant mFOLFIRINOX combined with hydroxychloroquine for pancreatic adenocarcinoma. It focuses on understanding the effects of this combination treatment before surgery.
The study evaluates the safety and tolerability of the treatment regimen. Researchers are interested in how the body responds to the treatment and any side effects that may occur.
- Who can participate: Adults with biopsy-proven pancreatic adenocarcinoma, without venous or arterial involvement, meeting specific health criteria can participate. Participants must be willing to undergo surgery and have no other active malignancies, except for basal cell carcinoma of the skin.
- Study details: Participants will take an investigational medication daily along with neoadjuvant mFOLFIRINOX.
- Study timelines: The study will last 56 days for the chemotherapy cycle, followed by surgery within 3 to 6 weeks.
How understandable was the trial content above?
Hard to understand
Easy to understand